<DOC>
	<DOCNO>NCT00873860</DOCNO>
	<brief_summary>This Phase 2a , randomize , double-blind , placebo-controlled , parallel-arm study evaluate efficacy safety 3 subcutaneous ( SC ) treatment regimens CAT-354 adult subject uncontrolled , moderate-to-severe , persistent asthma .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CAT-354</brief_title>
	<detailed_description>Study MI-CP199 , Phase 2a , randomize , double-blind , placebo-controlled , parallel-arm , multicenter study evaluate effect 3 SC treatment regimens CAT-354 asthma control adult uncontrolled , moderate-to-severe , persistent asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject Age 18 65 year time Screening Subjects must body mass index ( BMI ) 18 40 kilogram per square meter ( kg/m^2 ) Written informed consent obtain subject prior perform protocol related procedure , include Screening evaluation Physiciandiagnosed moderatetosevere , persistent asthma require treatment appropriate asthma controller medication Shows force expiratory volume 1 second ( FEV1 ) reversibility postbronchodilator great equal ( &gt; = ) 12 percent &gt; =200 milliliter ( mL ) show value previous test within last year , positive airway hyperresponsiveness ( AHR ) test result last year Prebronchodilator FEV 1 value &gt; =40 percent individual predict value Visits 1 3 Uncontrolled asthma consistent Expert Panel Report ( EPR ) 3 . In 2 4 week precede Screening , subject history 1 following : Daytime asthma symptom &gt; =2 days/week , Nighttime awaken &gt; =1 night/week , Salbutamol use &gt; =2 days/week An Asthma control questionnaire ( ACQ ) score &gt; =1.5 Visits 1 3 At least 1 occurrence asthma exacerbation past year require unscheduled medical encounter Men , unless surgically sterile , must likewise practice 2 effective method birth control ( condom spermicide ) must use precaution Day 1 Study Day 169 Otherwise healthy medical history physical examination age group A chest xray compute tomography ( CT ) scan within previous 12 month finding suggestive acute chronic respiratory pathology asthma Ability willingness complete followup period Day 169 require protocol . Known history allergy reaction component investigational product formulation Acute illness asthma start study History active infection within 4 week prior Screening , evidence clinically significant active infection , include ongoing chronic infection History ingestion untreated water location know infected parasite , result acute chronic diarrhea ; diagnosis parasitic infection within 6 month prior Screening Use immunosuppressive medication ( except oral prednisone 10 milligram/day ( mg/day ) inhale topical corticosteroid ) within 30 day randomization study Receipt immunoglobulin blood product within 30 day randomization study Receipt investigational drug therapy use biologicals include omalizumab within 6 month first dose investigational product study within 5 halflives investigational agent biologic , whichever long History know immunodeficiency disorder A positive hepatitis B surface antigen , hepatitis C virus antibody A positive human immunodeficiency virus test take antiretroviral medication , determine medical history and/or subject 's verbal report A live attenuate vaccination receive within 4 week prior Screening Previous medical history , evidence , intercurrent illness may compromise safety subject study History clinically significant abnormality electrocardiogram ( ECG ) opinion investigator Lactation ( woman ) History treatment alcohol drug abuse within past year History suggestive chronic obstructive pulmonary disease ( COPD ) cigarette smoke &gt; =10 packyears Evidence systemic disease physical examination History cancer , apart basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy less equal ( &lt; = ) 1 year prior Study Day 1 malignancy treat apparent success curative therapy &lt; =5 year prior entry Known exposure inhale occupational agent fume Any condition ( eg , cystic fibrosis [ CF ] COPD ) , opinion investigator , would interfere evaluation investigational product interpretation study result Individuals legally institutionalize Employees clinical study site individual involve conduct study , family member individual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CAT-354</keyword>
	<keyword>Tralokinumab</keyword>
	<keyword>Asthma</keyword>
</DOC>